A study evaluating efficacy of Dapagliflozin-low dose Pioglitazone combination for treatment of nonalcoholic fatty liver disease compared to Dapagliflozin-Glimepiride combination.

Trial Profile

A study evaluating efficacy of Dapagliflozin-low dose Pioglitazone combination for treatment of nonalcoholic fatty liver disease compared to Dapagliflozin-Glimepiride combination.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Pioglitazone (Primary) ; Glimepiride
  • Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2017 New trial record
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top